{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T20:26:41Z","timestamp":1790022401585,"version":"4.0.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"vor","delay-in-days":42,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-026-13151-7","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T12:16:16Z","timestamp":1775045776000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy of Ceftazidime\/Avibactam versus colistin methanesulfonate in treating pulmonary infections caused by Gram-negative bacillis after craniocerebral surgery and analysis of risk factors influencing clinical outcomes: a retrospective study"],"prefix":"10.1186","volume":"26","author":[{"given":"Xia","family":"Tian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lichao","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rufeng","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,1]]},"reference":[{"key":"13151_CR1","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.mcna.2019.11.001","volume":"104","author":"A Capizzi","year":"2020","unstructured":"Capizzi A, Woo J, Verduzco-Gutierrez M. Traumatic Brain Injury: An Overview of Epidemiology, Pathophysiology, and Medical Management. Med Clin North Am. 2020;104:213\u201338.","journal-title":"Med Clin North Am"},{"issue":"Suppl 1","key":"13151_CR2","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1111\/anae.15608","volume":"77","author":"MD Wiles","year":"2022","unstructured":"Wiles MD. Management of traumatic brain injury: a narrative review of current evidence. Anaesthesia. 2022;77(Suppl 1):102\u201312.","journal-title":"Anaesthesia"},{"key":"13151_CR3","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1007\/s12028-019-00773-w","volume":"32","author":"Y Li","year":"2020","unstructured":"Li Y, Liu C, Xiao W, Song T, Wang S, Incidence. Risk Factors, and Outcomes of Ventilator-Associated Pneumonia in Traumatic Brain Injury: A Meta-analysis. Neurocrit Care. 2020;32:272\u201385.","journal-title":"Neurocrit Care"},{"key":"13151_CR4","doi-asserted-by":"publisher","first-page":"35","DOI":"10.4266\/acc.2021.01193","volume":"37","author":"AA Chac\u00f3n-Aponte","year":"2022","unstructured":"Chac\u00f3n-Aponte AA, Dur\u00e1n-Vargas \u00c9A, Ar\u00e9valo-Carrillo JA, et al. Brain-lung interaction: a vicious cycle in traumatic brain injury. Acute Crit Care. 2022;37:35\u201344.","journal-title":"Acute Crit Care"},{"key":"13151_CR5","doi-asserted-by":"publisher","first-page":"91","DOI":"10.2174\/187152610790963528","volume":"10","author":"HC Emsley","year":"2010","unstructured":"Emsley HC, Hopkins SJ. Post-stroke immunodepression and infection: an emerging concept. Infect Disord Drug Targets. 2010;10:91\u20137.","journal-title":"Infect Disord Drug Targets"},{"key":"13151_CR6","first-page":"332","volume":"24","author":"CE Luyt","year":"2018","unstructured":"Luyt CE, H\u00e9kimian G, Koulenti D, Chastre J. Microbial cause of ICU-acquired pneumonia: hospital-acquired pneumonia versus ventilator-associated pneumonia. Curr Opin Crit Care. 2018;24:332\u20138.","journal-title":"Curr Opin Crit Care"},{"key":"13151_CR7","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1007\/s00134-020-05980-0","volume":"46","author":"L Papazian","year":"2020","unstructured":"Papazian L, Klompas M, Luyt CE. Ventilator-associated pneumonia in adults: a narrative review. Intensive Care Med. 2020;46:888\u2013906.","journal-title":"Intensive Care Med"},{"key":"13151_CR8","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s00134-014-3564-5","volume":"41","author":"GB Nair","year":"2015","unstructured":"Nair GB, Niederman MS. Ventilator-associated pneumonia: present understanding and ongoing debates. Intensive Care Med. 2015;41:34\u201348.","journal-title":"Intensive Care Med"},{"key":"13151_CR9","doi-asserted-by":"publisher","first-page":"107418","DOI":"10.1016\/j.ijantimicag.2024.107418","volume":"65","author":"C Liu","year":"2025","unstructured":"Liu C, Leng B, Xie M, et al. Comparing ceftazidime\/avibactam and polymyxin B for treating carbapenem-resistant organisms infections: A propensity score-matched retrospective cohort study. Int J Antimicrob Agents. 2025;65:107418.","journal-title":"Int J Antimicrob Agents"},{"key":"13151_CR10","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ijantimicag.2015.02.022","volume":"46","author":"HS Sader","year":"2015","unstructured":"Sader HS, Castanheira M, Flamm RK, Mendes RE, Farrell DJ, Jones RN. Ceftazidime\/avibactam tested against Gram-negative bacteria from intensive care unit (ICU) and non-ICU patients, including those with ventilator-associated pneumonia. Int J Antimicrob Agents. 2015;46:53\u20139.","journal-title":"Int J Antimicrob Agents"},{"key":"13151_CR11","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/phar.2209","volume":"39","author":"BT Tsuji","year":"2019","unstructured":"Tsuji BT, Pogue JM, Zavascki AP, et al. International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy. 2019;39:10\u201339.","journal-title":"Pharmacotherapy"},{"key":"13151_CR12","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1093\/cid\/ciaa061","volume":"72","author":"JR Strich","year":"2021","unstructured":"Strich JR, Ricotta E, Warner S, et al. Pharmacoepidemiology of Ceftazidime-Avibactam Use: A Retrospective Cohort Analysis of 210 US Hospitals. Clin Infect Dis. 2021;72:611\u201321.","journal-title":"Clin Infect Dis"},{"key":"13151_CR13","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1128\/AAC.00035-06","volume":"50","author":"PJ Bergen","year":"2006","unstructured":"Bergen PJ, Li J, Rayner CR, Nation RL. Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2006;50:1953\u20138.","journal-title":"Antimicrob Agents Chemother"},{"key":"13151_CR14","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/S1473-3099(06)70580-1","volume":"6","author":"J Li","year":"2006","unstructured":"Li J, Nation RL, Turnidge JD, et al. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis. 2006;6:589\u2013601.","journal-title":"Lancet Infect Dis"},{"key":"13151_CR15","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.diagmicrobio.2012.07.010","volume":"74","author":"PJ Bergen","year":"2012","unstructured":"Bergen PJ, Landersdorfer CB, Zhang J, et al. Pharmacokinetics and pharmacodynamics of \u2018old\u2019 polymyxins: what is new? Diagn Microbiol Infect Dis. 2012;74:213\u201323.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"13151_CR16","doi-asserted-by":"publisher","first-page":"e0177024","DOI":"10.1128\/spectrum.01770-24","volume":"13","author":"J Lu","year":"2025","unstructured":"Lu J, Ma Y, Cao Z, Zhu B, Fan L, Meng H. Efficacy of ceftazidime-avibactam with or without polymyxin for carbapenem-resistant Klebsiella pneumoniae infections after initial treatment with polymyxin. Microbiol Spectr. 2025;13:e0177024.","journal-title":"Microbiol Spectr"},{"key":"13151_CR17","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1007\/s40121-022-00682-0","volume":"11","author":"G Zheng","year":"2022","unstructured":"Zheng G, Cai J, Zhang L, et al. Ceftazidime\/Avibactam-Based Versus Polymyxin B-Based Therapeutic Regimens for the Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infection in Critically Ill Patients: A Retrospective Cohort Study. Infect Dis Ther. 2022;11:1917\u201334.","journal-title":"Infect Dis Ther"},{"key":"13151_CR18","doi-asserted-by":"publisher","first-page":"655","DOI":"10.2147\/IDR.S350976","volume":"15","author":"J Chen","year":"2022","unstructured":"Chen J, Liang Q, Chen X, et al. Ceftazidime\/Avibactam versus Polymyxin B in the Challenge of Carbapenem-Resistant Pseudomonas aeruginosa Infection. Infect Drug Resist. 2022;15:655\u201367.","journal-title":"Infect Drug Resist"},{"key":"13151_CR19","doi-asserted-by":"publisher","first-page":"780940","DOI":"10.3389\/fphar.2021.780940","volume":"12","author":"J Fang","year":"2021","unstructured":"Fang J, Li H, Zhang M, et al. Efficacy of Ceftazidime-Avibactam Versus Polymyxin B and Risk Factors Affecting Clinical Outcomes in Patients With Carbapenem-Resistant Klebsiella pneumoniae Infections a Retrospective Study. Front Pharmacol. 2021;12:780940.","journal-title":"Front Pharmacol"},{"key":"13151_CR20","doi-asserted-by":"publisher","first-page":"1198926","DOI":"10.3389\/fmicb.2023.1198926","volume":"14","author":"S Xiao","year":"2023","unstructured":"Xiao S, Fu Q, Miao Y, et al. Clinical efficacy and drug resistance of ceftazidime-avibactam in the treatment of Carbapenem-resistant gram-negative bacilli infection. Front Microbiol. 2023;14:1198926.","journal-title":"Front Microbiol"},{"key":"13151_CR21","doi-asserted-by":"publisher","first-page":"106872","DOI":"10.1016\/j.ijantimicag.2023.106872","volume":"62","author":"J Qu","year":"2023","unstructured":"Qu J, Xu J, Liu Y, Hu C, Zhong C, Lv X. Real-world effectiveness of ceftazidime\/avibactam versus polymyxin B in treating patients with carbapenem-resistant Gram-negative bacterial infections. Int J Antimicrob Agents. 2023;62:106872.","journal-title":"Int J Antimicrob Agents"},{"key":"13151_CR22","doi-asserted-by":"publisher","first-page":"e61","DOI":"10.1093\/cid\/ciw353","volume":"63","author":"AC Kalil","year":"2016","unstructured":"Kalil AC, Metersky ML, Klompas M, et al. Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016;63:e61\u2013111.","journal-title":"Clin Infect Dis"},{"key":"13151_CR23","doi-asserted-by":"publisher","first-page":"786","DOI":"10.3389\/fphar.2020.00786","volume":"11","author":"L Li","year":"2020","unstructured":"Li L, Li X, Xia Y, et al. Recommendation of Antimicrobial Dosing Optimization During Continuous Renal Replacement Therapy. Front Pharmacol. 2020;11:786.","journal-title":"Front Pharmacol"},{"key":"13151_CR24","doi-asserted-by":"crossref","unstructured":"Krapp F, Grant JL, Sutton SH, Ozer EA, Barr VO. Treating complicated carbapenem-resistant enterobacteriaceae infections with ceftazidime\/avibactam: a retrospective study with molecular strain characterisation. Int J Antimicrob Agents. 2017;49:770\u20133.","DOI":"10.1016\/j.ijantimicag.2017.01.018"},{"key":"13151_CR25","doi-asserted-by":"publisher","first-page":"e0021321","DOI":"10.1128\/JCM.00213-21","volume":"59","author":"R Humphries","year":"2021","unstructured":"Humphries R, Bobenchik AM, Hindler JA, Schuetz AN. Overview of Changes to the Clinical and Laboratory Standards Institute Performance Standards for Antimicrobial Susceptibility Testing, M100, 31st Edition. J Clin Microbiol. 2021;59:e0021321.","journal-title":"J Clin Microbiol"},{"key":"13151_CR26","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1016\/j.cmi.2020.06.007","volume":"26","author":"MC Arendrup","year":"2020","unstructured":"Arendrup MC, Friberg N, Mares M, Kahlmeter G, Meletiadis J, Guinea J. How to interpret MICs of antifungal compounds according to the revised clinical breakpoints v. 10.0 European committee on antimicrobial susceptibility testing (EUCAST). Clin Microbiol Infect. 2020;26:1464\u201372.","journal-title":"Clin Microbiol Infect"},{"key":"13151_CR27","doi-asserted-by":"publisher","first-page":"65","DOI":"10.5492\/wjccm.v5.i1.65","volume":"5","author":"A Koutsoukou","year":"2016","unstructured":"Koutsoukou A, Katsiari M, Orfanos SE, et al. Respiratory mechanics in brain injury: A review. World J Crit Care Med. 2016;5:65\u201373.","journal-title":"World J Crit Care Med"},{"key":"13151_CR28","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1089\/neu.2019.6885","volume":"37","author":"SJ McDonald","year":"2020","unstructured":"McDonald SJ, Sharkey JM, Sun M, et al. Beyond the Brain: Peripheral Interactions after Traumatic Brain Injury. J Neurotrauma. 2020;37:770\u201381.","journal-title":"J Neurotrauma"},{"issue":"Suppl 1","key":"13151_CR29","doi-asserted-by":"publisher","first-page":"S87","DOI":"10.1089\/neu.2007.9982","volume":"24","author":"SL Bratton","year":"2007","unstructured":"Bratton SL, Chestnut RM, Ghajar J, et al. Guidelines for the management of severe traumatic brain injury. XIV. Hyperventilation. J Neurotrauma. 2007;24(Suppl 1):S87\u201390.","journal-title":"J Neurotrauma"},{"key":"13151_CR30","first-page":"137","volume":"26","author":"C Robba","year":"2020","unstructured":"Robba C, Bonatti G, Pelosi P, Citerio G. Extracranial complications after traumatic brain injury: targeting the brain and the body. Curr Opin Crit Care. 2020;26:137\u201346.","journal-title":"Curr Opin Crit Care"},{"key":"13151_CR31","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1186\/s13054-019-2662-8","volume":"23","author":"C Robba","year":"2019","unstructured":"Robba C, Bonatti G, Battaglini D, Rocco PRM, Pelosi P. Mechanical ventilation in patients with acute ischaemic stroke: from pathophysiology to clinical practice. Crit Care. 2019;23:388.","journal-title":"Crit Care"},{"key":"13151_CR32","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s12028-009-9242-8","volume":"11","author":"L Mascia","year":"2009","unstructured":"Mascia L. Acute lung injury in patients with severe brain injury: a double hit model. Neurocrit Care. 2009;11:417\u201326.","journal-title":"Neurocrit Care"},{"key":"13151_CR33","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1097\/CCM.0b013e31828a3f4d","volume":"41","author":"J Elmer","year":"2013","unstructured":"Elmer J, Hou P, Wilcox SR, et al. Acute respiratory distress syndrome after spontaneous intracerebral hemorrhage*. Crit Care Med. 2013;41:1992\u20132001.","journal-title":"Crit Care Med"},{"key":"13151_CR34","doi-asserted-by":"publisher","first-page":"3483","DOI":"10.21037\/jtd.2017.08.149","volume":"9","author":"A Bruni","year":"2017","unstructured":"Bruni A, Garofalo E, Pelaia C, Longhini F, Navalesi P. Mechanical ventilation in brain injured patients: seeing the forest for the trees. J Thorac Dis. 2017;9:3483\u20137.","journal-title":"J Thorac Dis"},{"key":"13151_CR35","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1093\/cid\/ciw243","volume":"63","author":"D van Duin","year":"2016","unstructured":"van Duin D, Bonomo RA. Ceftazidime\/Avibactam and Ceftolozane\/Tazobactam: Second-generation \u03b2-Lactam\/\u03b2-Lactamase Inhibitor Combinations. Clin Infect Dis. 2016;63:234\u201341.","journal-title":"Clin Infect Dis"},{"key":"13151_CR36","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.1093\/jac\/dkw239","volume":"71","author":"M Falcone","year":"2016","unstructured":"Falcone M, Paterson D. Spotlight on ceftazidime\/avibactam: a new option for MDR Gram-negative infections. J Antimicrob Chemother. 2016;71:2713\u201322.","journal-title":"J Antimicrob Chemother"},{"key":"13151_CR37","doi-asserted-by":"crossref","unstructured":"Yin D, Wu S, Yang Y et al. Results from the China Antimicrobial Surveillance Network (CHINET) in 2017 of the in vitro activities of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against clinical isolates of enterobacteriaceae and pseudomonas aeruginosa. Antimicrob Agents Chemother. 2019;63.","DOI":"10.1128\/AAC.02431-18"},{"key":"13151_CR38","doi-asserted-by":"crossref","unstructured":"Vena A, Giacobbe DR, Castaldo N, et al. Clinical experience with ceftazidime-avibactam for the treatment of infections due to multidrug-resistant gram-negative bacteria other than carbapenem-resistant enterobacterales. Antibiotics (Basel). 2020;9.","DOI":"10.3390\/antibiotics9020071"},{"key":"13151_CR39","doi-asserted-by":"crossref","unstructured":"Shields RK, Nguyen MH, Chen L, et al. Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant klebsiella pneumoniae bacteremia. Antimicrob Agents Chemother. 2017;61.","DOI":"10.1128\/AAC.00883-17"},{"key":"13151_CR40","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1093\/cid\/cix783","volume":"66","author":"D van Duin","year":"2018","unstructured":"van Duin D, Lok JJ, Earley M, et al. Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae. Clin Infect Dis. 2018;66:163\u201371.","journal-title":"Clin Infect Dis"},{"key":"13151_CR41","doi-asserted-by":"publisher","first-page":"ofz522","DOI":"10.1093\/ofid\/ofz522","volume":"6","author":"SCJ Jorgensen","year":"2019","unstructured":"Jorgensen SCJ, Trinh TD, Zasowski EJ, et al. Real-World Experience With Ceftazidime-Avibactam for Multidrug-Resistant Gram-Negative Bacterial Infections. Open Forum Infect Dis. 2019;6:ofz522.","journal-title":"Open Forum Infect Dis"},{"key":"13151_CR42","doi-asserted-by":"publisher","first-page":"107021","DOI":"10.1016\/j.ijantimicag.2023.107021","volume":"63","author":"C Xu","year":"2024","unstructured":"Xu C, Zeng F, Huang Y, et al. Clinical efficacy of ceftazidime\/avibactam combination therapy for severe hospital-acquired pulmonary infections caused by carbapenem-resistant and difficult-to-treat Pseudomonas aeruginosa. Int J Antimicrob Agents. 2024;63:107021.","journal-title":"Int J Antimicrob Agents"},{"key":"13151_CR43","doi-asserted-by":"crossref","unstructured":"Fois M, De Vito A, Cherchi F, et al. Efficacy and safety of ceftazidime-avibactam alone versus ceftazidime-avibactam plus fosfomycin for the treatment of hospital-acquired pneumonia and ventilator-associated pneumonia: a multicentric retrospective study from the SUSANA cohort. Antibiot (Basel). 2024;13.","DOI":"10.3390\/antibiotics13070616"},{"key":"13151_CR44","doi-asserted-by":"publisher","first-page":"107152","DOI":"10.1016\/j.ijantimicag.2024.107152","volume":"63","author":"J Hu","year":"2024","unstructured":"Hu J, Zha L, Yu YW, et al. Efficacy of ceftazidime-avibactam in the treatment of carbapenem-resistant Klebsiella pneumoniae infections: Focus on solid organ transplantation recipients. Int J Antimicrob Agents. 2024;63:107152.","journal-title":"Int J Antimicrob Agents"},{"key":"13151_CR45","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s15010-023-02094-9","volume":"52","author":"RA Sree","year":"2024","unstructured":"Sree RA, Gupta A, Gupta N, et al. Ceftazidime-avibactam alone or in combination with Aztreonam versus Polymyxins in the management of carbapenem-Resistant Klebsiella pneumoniae nosocomial Infections (CAPRI study): a retrospective cohort study from South India. Infection. 2024;52:429\u201337.","journal-title":"Infection"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-13151-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13151-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13151-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T23:24:34Z","timestamp":1778628274000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-13151-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["13151"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-13151-7","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,1]]},"assertion":[{"value":"1 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All experiments performed in this study were in accordance with the ethical standards of the Second Affiliated Hospital of Shandong First Medical University and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Ethical approval for this study was obtained from the ethics committee of the Second Affiliated Hospital of Shandong First Medical University (approval no. 2025-067; Taian, China). The ethics committee waived the need for informed consent from patients due to the retrospective and anonymous characters of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"935"}}